Taipei Medical University & National Chiao Tung University Join Hands- Discovering New Drugs for Breast Cancer

Source: College of Medical Science and Technology

Published on 2020-03-13

For the 37th straight year, cancer tops the list of the 10 leading causes of death in Taiwan.

To increase the effectiveness of targeted cancer therapies, Taipei Medical University (TMU) and National Chiao Tung University (NCTU) collaborate in developing the Cancer Membrane Protein-regulated Networks (CaMPNets), involving nearly 2,000 membrane proteins (MPs) and their interactions with 15 human cancers. The research was entitled Membrane Protein-regulated Networks across Human Cancers, published in a top-tier scientific journal, Nature Communications, July 16, 2019. In addition to the unprecedented development, the research team finds a type of new drug, patent pending now in several countries, capable of inhibiting the transfer of breast cancer.

 Did you know?

Membrane proteins (MPs) are currently the most important target classes for disease diagnosis and treatment, also becoming one of the most complex topics in medical research. Meanwhile, studies have shown a close relation between MPs and several types of cancers. If more studies were carried out on the mechanism of MPs and their regulated pathways, researchers would be able to form cancer cells, in turn, identify corresponding treatments. This could have a major impact on cancer diagnosis and targeted therapies development.

According to Professor Yuan-Soon Ho from TMU, breast cancer growth caused by smoking is related to nicotine receptors, confirmed by TMU Breast Cancer Translational Research Team in 2010 with the research published in Journal of the National Cancer Institute, a leading medical journal. Therefore, the future research in breast cancer treatment will focus on developing high-efficiency drugs that can target nicotine receptors and HER-2 as they are two known MPs

In 2010, Prof. Yuan-Soon Ho and the TMU research team confirmed that nicotine receptors are related to smoking-induced breast cancer.

Through the cross-school collaboration, research teams from TMU and NCTU develop prognostic biomarkers and therapeutic drugs using MPs. In addition, a type of antidepressant is found capable of inhibiting breast cancer metastasis. After tested on cultured cells and animals, the new drug is proven effective in inhibiting the transfer of triple-negative breast cancer (TNBC).

Prof. Yuan-Soon Ho (4th from right) and the research team at the press conference

TMU Study Abroad Info Session

Download the slides for getting more information about the study abroad opportunities in TMU

TMU International Outstanding Alumni-Usman Iqbal

People are always thinking about where everyone else is going. They don’t consider that smaller countries can also have good quality education.—Dr. Usman Iqbal

TMU PhD Student Fang-Chi Hsu Went to Johns Hopkins University for a Year of Research upon Receiving a Subsidy Provided by the Ministry of Science and Technology

Encouraged by teachers and classmates, Fang-Chi Hsu, a PhD Student of the PhD Program for Transcriptional Medicine of the College of Medical Science and Technology, Taipei Medical University, departed for Sidney Kimmel Comprehensive Cancer Center (SKCCC) of Johns Hopkins University (JHU) in 2020 for a year of research upon receiving a subsidy through the Graduate Student Study Abroad Program provided by the Ministry of Science and Technology.

TMU special digital mini-exhibition cultivates future generations of talents

Taipei Medical University and National Palace Museum jointly held the National Palace Museum X TMU Pop Up Exhibition special series of digital mini-exhibitions at the end of December 2019 on the University campus.

RISE worldwide 2021

In this program research groups, laboratories and doctoral students can apply to host a motivated and wellqualified student from Germany.

Taipei Medical University spin-out company launches “ASKiN”, providing an online dermatologist consultation platform accessible through the LINE App

DermAI Co., Ltd., a Taipei Medical University spin-out, has launched the online dermatologist consultation platform “ASKiN.”